2Ii H, Hontani N, Toshida I, et al. Group IVA phospholipase A2 associated production of MMP-9 in macrophages and formation of atherosclerotic lesions [J]. Biol Pharm Bull, 2008, 31 (3):363-368. 被引量：1
3Nambi V, Morrison AC, Hooqeveen RC, et al. Matrix Metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study [J]. Tex Heart Inst J, 2008, 35(4) :388-394. 被引量：1
4Chang CJ, Hsu LA, Ko YH, et al. Thrombin regulates matrix metalloproteinase-9 expression in human monocytes[J]. Biochem Biophys Res Commun, 2009,385(2): 241-246. 被引量：1
5Parks WC, Wilson CL, Lopez Boado YS, et al. Matrix metalloproteinases as modulators of inflammation and innate immunity [J]. Nat Rev Immunol, 2004, 4 (8): 617-629. 被引量：1
6Lancelot E, Amirbekian V, Briggern I, et al. Evaluation of Matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach [J]. Arterioscler Thromb Vasc Biol, 2008,28(3):425-432. 被引量：1
7Libby P. The Molecular mechanisms of the thrombotic complications of atherosclerosis[J]. J Intern Med, 2008, 263(5) :517-527. 被引量：1
8Luttun A, Lutqens E, Manderveld A, et al. Loss of matrix metalioproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E deficient mice against atherosclerotic media destruction but differentially affects plaque growth [J]. Circulation, 2004,109(11):1408-1414. 被引量：1
9Inokubo Y , Hanada H, Ishizaka H, et al . Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome [J]. Am Heart J, 2001,141(2):211-217. 被引量：1
10Ardans JA, Blum A, Mangan PR, et al. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes [J]. Arterioscler Thromb Vasc Biol, 2001,21(8) :1265-1268. 被引量：1
